How have OCSAW shares performed in 2024?

Oculis' stock was trading at $1.50 at the beginning of 2024. Since then, OCSAW stock has increased by 34.0% and is now trading at $2.0101. View the best growth stocks for 2024 here .

How do I buy shares of Oculis?

Shares of OCSAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:OCSAW

Oculis (OCSAW) Stock Price, News & Analysis

→ Gold Mania (From Stansberry Research) (Ad)

Free OCSAW Stock Alerts

$2.01

0.00 (0.00%)

(As of 05/2/2024 ET)

Compare

Today's Range: $2.01
▼
$2.01
50-Day Range: $1.80
▼
$2.94
52-Week Range: $0.55
▼
$2.98

Volume: N/A
Average Volume: 9,257 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials SEC Filings Social Media

Get Oculis alerts:

Ad Porter & Company

The biggest energy story ever?

Discover why I’m calling this one of the biggest developments in the global energy market since the shale revolution… why everything you’ve ever been told about Trump’s environmental record is a lie…

For the full story, click here.

About Oculis

Oculis Holding AG, a biopharmaceutical company, develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidates in development includes OCS-01, a topical retinal candidate for diabetic macular edema; OCS-02, a topical biologic candidate for dry eye disease; and OCS-05, a disease modifying candidate for acute optic neuritis and other neuro-ophtha disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The company is based in Zug, Switzerland.

OCSAW Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OCSAW Stock News Headlines

No headlines for this company have been tracked by MarketBeat.com

Receive OCSAW Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Oculis and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Biotechnology
Sub-Industry: N/A
Current Symbol: NASDAQ:OCSAW
CUSIP: N/A
CIK: 1953530
Web: www.oculis.com
Phone: 41-58-810-0182
Fax: N/A
Employees: 32
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: N/A
Quick Ratio: N/A

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: N/A
Price / Book: N/A

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: N/A

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Dr. Riad Sherif M.B.A. (Age 55)
M.D., CEO & Director
Ms. Sylvia Cheung (Age 48)
Chief Financial Officer
Mr. Weibo Ding (Age 52)
Global COO & GM of China
Dr. Bastian Dehmel (Age 52)
Chief Devel. Officer & Head of Devel.
Dr. Joanne Chang M.D. (Age 62)
Ph.D., Head of Medical Affairs & Chief Medical Officer
Mr. Páll Ragnar Jóhannesson
Chief Strategy Officer

Key Competitors

View All Competitors

OCSAW Stock Analysis - Frequently Asked Questions

How have OCSAW shares performed in 2024?: Oculis' stock was trading at $1.50 at the beginning of 2024. Since then, OCSAW stock has increased by 34.0% and is now trading at $2.0101.
View the best growth stocks for 2024 here.
How do I buy shares of Oculis?: Shares of OCSAW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:OCSAW) was last updated on 5/2/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial